A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to focus on GLP-1 products.